| 货号 | 19563-25mg |
| 描述 | Cobimetinib is a potent, orally available inhibitor of MEK1 (IC50 = 4.2 nM).1,2 It shows more than 100-fold selectivity for MEK when tested against a panel of more than 100 serine-threonine and tyrosine kinases. Cobimetinib induces differentiation and apoptosis in cancer cell lines and is more effective when combined with additional inhibitors, like PLX4032 (Item No. 10618).2,3,4 |
| 别名 | GDC-0973;RG-7420;XL518; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Akinleye, A.,Furgan, M.,Mukhi, N., et al. MEK and the inhibitors: From bench to bedside. J.Hematol.Oncol. 6, 1-11 (2013). 2.Hoeflich, K.P.,Merchang, M.,Orr, C., et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 72(1), 210-219 (2012). 3.Medina, T.M., and Lewis, K.D. The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: A highlight of vemurafenib and cobimetinib. Onco Targets Ther. 2016:9, 3739-3752 (2016). 4.Sing, A.,Ruan, Y.,Tippett, T., et al. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. J.Exp.Clin.Cancer Res. 34:104, (2015). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 531.3 |
| 分子式 | C21H21F3IN3O2 |
| CAS号 | 934660-93-2 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |